Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig.

Yin DP, Sankary HN, Williams J, Krieger N, Fathman CG
Transplantation. 1996 62 (11): 1537-9

PMID: 8970603 · DOI:10.1097/00007890-199612150-00001

This study was designed to investigate the effectiveness of combined perioperative anti-CD4 and human (h)CTLA4Ig therapy in preventing allorejection of small bowel transplantation in high-responder Lewis rat recipients of ACI grafts. Anti-CD4 (5 mg/kg x 4 days) or hCTLA4Ig (0.5 mg/rat x 2 days) therapy alone delayed, but did not prevent, allograft rejection after small bowel transplantation of ACI into Lewis rats. All grafts were rejected in 18 and 10 days, respectively. However, a regimen of anti-CD4 (5 mg/kg x 4 days) combined with hCTLA4Ig (0.5 mg/rat x 2 days) allowed indefinite survival of ACI small bowel allografts. Second donor-matched heart grafts were permanently accepted, whereas third-party (Sprague-Dawley) heart allografts were rejected by the tolerant recipients. These data suggest that these two reagents produced a synergistic effect in preventing allorejection of small bowel transplantation.

MeSH Terms (22)

Abatacept Animals Antibodies Antigens, CD Antigens, Differentiation CD4 Antigens CTLA-4 Antigen Drug Therapy, Combination Graft Rejection Humans Immune Tolerance Immunoconjugates Immunoglobulin Fc Fragments Immunosuppressive Agents Intestine, Small Male Rats Rats, Inbred ACI Rats, Inbred Lew Rats, Sprague-Dawley Recombinant Fusion Proteins Transplantation, Homologous

Connections (1)

This publication is referenced by other Labnodes entities: